array:24 [ "pii" => "S244438242100002X" "issn" => "24443824" "doi" => "10.1016/j.gastre.2020.05.007" "estado" => "S300" "fechaPublicacion" => "2021-01-01" "aid" => "1583" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2020" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2021;44:28-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0210570520302430" "issn" => "02105705" "doi" => "10.1016/j.gastrohep.2020.05.012" "estado" => "S300" "fechaPublicacion" => "2021-01-01" "aid" => "1583" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2021;44:28-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENTÍFICA</span>" "titulo" => "Colitis inducida por inmunoterapia: ¿puede ser una colitis ulcerosa?" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "28" "paginaFinal" => "29" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Immunotherapy-induced colitis: Could it be ulcerative colitis?" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 915 "Ancho" => 905 "Tamanyo" => 127312 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Colitis izquierda severa.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Isabel Moreno Moraleda, Marta Lázaro Sáez, Carmelo Diéguez Castillo, Álvaro Hernández Martínez" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Isabel" "apellidos" => "Moreno Moraleda" ] 1 => array:2 [ "nombre" => "Marta" "apellidos" => "Lázaro Sáez" ] 2 => array:2 [ "nombre" => "Carmelo" "apellidos" => "Diéguez Castillo" ] 3 => array:2 [ "nombre" => "Álvaro" "apellidos" => "Hernández Martínez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S244438242100002X" "doi" => "10.1016/j.gastre.2020.05.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S244438242100002X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570520302430?idApp=UINPBA00004N" "url" => "/02105705/0000004400000001/v1_202101130647/S0210570520302430/v1_202101130647/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S244438242100016X" "issn" => "24443824" "doi" => "10.1016/j.gastre.2020.06.008" "estado" => "S300" "fechaPublicacion" => "2021-01-01" "aid" => "1582" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2021;44:29-31" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Severe intrahepatic cholestasis as the initial manifestation of light chain amyloidosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "29" "paginaFinal" => "31" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Colestasis intrahepática grave como manifestación inicial de la amiloidosis por depósito de cadenas ligeras" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1737 "Ancho" => 1674 "Tamanyo" => 397469 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">(A) Liver cell trabeculae are compressed by marked amyloid deposition in the sinusoids. Abundant acellular pink material (black arrows) on a H&E stain is seen in this high magnification picture. (B) The presence of amyloid was confirmed by apple green birefringence on Congo Red staining with polarized microscopy. The deposit was observed both in the sinusoids (arrows) as well as in the vessels wall (black star). (C, D) FDG-PET showed signs of hepatic infiltration (SUVmax<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>4.3) and axial skeleton bone marrow heterogeneous hypercaptation (SUVmax L2<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3.2).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Diego Martínez-Acitores de la Mata, Silvia Bravo Meléndez, Candela Ceballos Bolaños, Irene Amat Villegas, María Carmen Mateos Rodriguez, Mara Pilar Huarte Muniesa, Susana Oquiñena Legaz, Montserrat Alvarellos Outerio, Sara Pérez Ricarte" "autores" => array:9 [ 0 => array:2 [ "nombre" => "Diego" "apellidos" => "Martínez-Acitores de la Mata" ] 1 => array:2 [ "nombre" => "Silvia" "apellidos" => "Bravo Meléndez" ] 2 => array:2 [ "nombre" => "Candela" "apellidos" => "Ceballos Bolaños" ] 3 => array:2 [ "nombre" => "Irene Amat" "apellidos" => "Villegas" ] 4 => array:2 [ "nombre" => "María Carmen" "apellidos" => "Mateos Rodriguez" ] 5 => array:2 [ "nombre" => "Mara Pilar" "apellidos" => "Huarte Muniesa" ] 6 => array:2 [ "nombre" => "Susana" "apellidos" => "Oquiñena Legaz" ] 7 => array:2 [ "nombre" => "Montserrat" "apellidos" => "Alvarellos Outerio" ] 8 => array:2 [ "nombre" => "Sara" "apellidos" => "Pérez Ricarte" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S244438242100016X?idApp=UINPBA00004N" "url" => "/24443824/0000004400000001/v2_202102250807/S244438242100016X/v2_202102250807/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2444382421000031" "issn" => "24443824" "doi" => "10.1016/j.gastre.2020.05.008" "estado" => "S300" "fechaPublicacion" => "2021-01-01" "aid" => "1586" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2021;44:27-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Oral intolerance for esophagitis secondary to alendronic acid" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "27" "paginaFinal" => "28" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Intolerancia oral por esofagitis secundaria a ácido alendrónico" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1227 "Ancho" => 1675 "Tamanyo" => 125456 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Image of the distal segment of the oesophagus with severe oesophagitis covering the entire circumference, in addition to friable mucosa, whitish exudate and ulcerations.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Lucía Zabalza San Martín, Cristina Saldaña Dueñas, Marta Gómez Alonso, Gregorio Aisa Ribera" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Lucía" "apellidos" => "Zabalza San Martín" ] 1 => array:2 [ "nombre" => "Cristina" "apellidos" => "Saldaña Dueñas" ] 2 => array:2 [ "nombre" => "Marta" "apellidos" => "Gómez Alonso" ] 3 => array:2 [ "nombre" => "Gregorio" "apellidos" => "Aisa Ribera" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210570520302466" "doi" => "10.1016/j.gastrohep.2020.05.015" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570520302466?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382421000031?idApp=UINPBA00004N" "url" => "/24443824/0000004400000001/v2_202102250807/S2444382421000031/v2_202102250807/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Immunotherapy-induced colitis: Could it be ulcerative colitis?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "28" "paginaFinal" => "29" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Isabel Moreno Moraleda, Marta Lázaro Sáez, Carmelo Diéguez Castillo, Álvaro Hernández Martínez" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Isabel" "apellidos" => "Moreno Moraleda" "email" => array:1 [ 0 => "isa_19_92@hotmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Marta" "apellidos" => "Lázaro Sáez" ] 2 => array:2 [ "nombre" => "Carmelo" "apellidos" => "Diéguez Castillo" ] 3 => array:2 [ "nombre" => "Álvaro" "apellidos" => "Hernández Martínez" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "UGC de Aparato Digestivo, Hospital Universitario Torrecárdenas, Almería, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Colitis inducida por inmunoterapia: ¿puede ser una colitis ulcerosa?" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 546 "Ancho" => 905 "Tamanyo" => 78909 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Erythema multiforme: erythematous, annular "target" lesions.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Immunotherapy has revolutionised cancer treatment in recent years. However, its side effects include so-called immune-mediated side effects, mainly dermatological and gastrointestinal toxicity.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Immunotherapy-induced colitis is a common adverse effect which is difficult to distinguish from primary ulcerative colitis, both endoscopically and histologically, creating a major diagnostic challenge for gastroenterologists.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">We report the case of a patient on treatment with pembrolizumab for metastatic melanoma who developed colitis, with biopsies consistent with ulcerative colitis. Was this ulcerative colitis or simply colitis-like?</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Case report</span><p id="par0020" class="elsevierStylePara elsevierViewall">This was a 61-year-old man diagnosed with melanoma with lung metastases. After starting cancer therapy with pembrolizumab, the patient consulted with erythematous, annular skin lesions on his limbs (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>), associated with bloody diarrhoea with more than 15 bowel movements per day.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">A colonoscopy showed severe active left colitis, and biopsies were consistent with ulcerative colitis (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). With uncertainty over a possible toxic origin or the onset of inflammatory bowel disease, he was started on steroid therapy, with slight clinical improvement, although in the end he needed infliximab due to steroid dependence.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">In view of his history of melanoma, it was decided to administer only two induction doses with infliximab. However, a month later he returned with the same symptoms and it was decided to start treatment with another biological agent, in this case vedolizumab, because of its safety profile in cancer patients.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The patient subsequently followed a good clinical course, remaining asymptomatic from an intestinal point of view. Two months later, a repeat CT scan revealed progression of the cancer with cannonball lung metastases and bone metastases.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Discussion</span><p id="par0040" class="elsevierStylePara elsevierViewall">The differential diagnosis of enterocolitis in cancer patients includes the classic colitis associated with antibiotics and neutropenic colitis. However, other aetiologies, such drug-induced (in this case, secondary to immunotherapy drugs), are not always taken into account.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Pembrolizumab is an immunotherapy drug approved for the treatment of metastatic melanoma. With the mechanism of action of this monoclonal antibody, it is only logical to expect autoimmune side effects deriving from the production of autoreactive T lymphocytes which act against different body tissues.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Pembrolizumab-induced colitis is very rare (<1%), generally affecting the descending colon and becoming apparent with diarrhoea some six to 16 weeks after starting therapy. Less common gastrointestinal adverse effects include: mouth ulcers, oesophagitis, gastritis and perforation.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">Flare-ups are treated with corticosteroids. According to clinical experience, if there is no clear improvement in symptoms after three days of treatment with intravenous corticosteroids, it can be considered steroid-refractory colitis. In these cases, combination treatment with infliximab may be beneficial.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> If symptoms persist after the first dose, a second dose can be given after two weeks. In some cases it is considered maintenance therapy due to the episodes of relapse seen, despite mucosal healing of the colon.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4</span></a> If symptoms do not improve after infliximab is used or if anti-TNF〈 is contraindicated, vedolizumab should be considered.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">Although there are very few reported cases in the literature, due to the boom in immunotherapy in recent years, an increased frequency of adverse reactions could be seen, and the possibility has to be taken into account. Although an association has been found between immune-mediated effects and a favourable tumour response,<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> in these cases, treatment must be stopped and the toxicity must be treated, as the prognosis and outcome can be fatal.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Case report" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Discussion" ] 3 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Moreno Moraleda I, Lázaro Sáez M, Diéguez Castillo C, Hernández Martínez Á. Colitis inducida por inmunoterapia: ¿puede ser una colitis ulcerosa? Gastroenterol Hepatol. 2021;44:29–30.</p>" ] ] "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 546 "Ancho" => 905 "Tamanyo" => 78909 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Erythema multiforme: erythematous, annular "target" lesions.</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 915 "Ancho" => 905 "Tamanyo" => 127312 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Severe left colitis.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Naidoo" 1 => "D.B. Page" 2 => "B.T. Li" 3 => "L.C. Connell" 4 => "K. Schindler" 5 => "M.E. Lacouture" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdv383" "Revista" => array:5 [ "tituloSerie" => "Ann Oncol." "fecha" => "2015" "volumen" => "26" "paginaInicial" => "2375" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26371282" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Champiat" 1 => "O. Lambotte" 2 => "E. Barreau" 3 => "R. Belkhir" 4 => "A. Berdelou" 5 => "F. Carbonnel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdv623" "Revista" => array:5 [ "tituloSerie" => "Ann Oncol." "fecha" => "2016" "volumen" => "27" "paginaInicial" => "559" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26715621" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.Y. Wang" 1 => "J.E. Salem" 2 => "J.V. Cohen" 3 => "S. Chandra" 4 => "C. Menzer" 5 => "F. Ye" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamaoncol.2018.3923" "Revista" => array:5 [ "tituloSerie" => "JAMA Oncol." "fecha" => "2018" "volumen" => "4" "paginaInicial" => "1721" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30242316" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "National Comprehensive Cancer Network. Management of immunerelated adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.R. Brahmer" 1 => "C. Lacchetti" 2 => "B.J. Schneider" 3 => "M.B. Atkins" 4 => "K.J. Brassil" 5 => "J.M. Caterino" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2017.77.6385" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol." "fecha" => "2018" "volumen" => "36" "paginaInicial" => "1714" "paginaFinal" => "1768" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29442540" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.B.A.G. Haanen" 1 => "F. Carbonnel" 2 => "C. Robert" 3 => "K.M. Kerr" 4 => "S. Peters" 5 => "J. Larkin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdx225" "Revista" => array:6 [ "tituloSerie" => "Ann Oncol." "fecha" => "2017" "volumen" => "28" "paginaInicial" => "iv119" "paginaFinal" => "iv142" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28881921" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/24443824/0000004400000001/v2_202102250807/S244438242100002X/v2_202102250807/en/main.assets" "Apartado" => array:4 [ "identificador" => "77930" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Scientific letter" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/24443824/0000004400000001/v2_202102250807/S244438242100002X/v2_202102250807/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S244438242100002X?idApp=UINPBA00004N" ]
Journal Information
Share
Download PDF
More article options
Scientific letter
Immunotherapy-induced colitis: Could it be ulcerative colitis?
Colitis inducida por inmunoterapia: ¿puede ser una colitis ulcerosa?
Isabel Moreno Moraleda
, Marta Lázaro Sáez, Carmelo Diéguez Castillo, Álvaro Hernández Martínez
Corresponding author
UGC de Aparato Digestivo, Hospital Universitario Torrecárdenas, Almería, Spain